The estimated Net Worth of Justin Leong is at least $15.2 Milion dollars as of 5 August 2024. Mr. Leong owns over 48,000 units of Resmed stock worth over $4,739,974 and over the last 4 years he sold RMD stock worth over $10,419,360. In addition, he makes $0 as President – Asia and Latin America at Resmed.
Sign up
Mr. Leong RMD stock SEC Form 4 insiders trading
Justin has made over 3 trades of the Resmed stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 48,000 units of RMD stock worth $10,419,360 on 5 August 2024.
The largest trade he's ever made was selling 48,000 units of Resmed stock on 5 August 2024 worth over $10,419,360. On average, Justin trades about 6,431 units every 124 days since 2020. As of 5 August 2024 he still owns at least 18,741 units of Resmed stock.
You can see the complete history of Mr. Leong stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Justin Leong biography
Justin M. W. Leong serves as President – Asia and Latin America of the Company. Justin was a director at London based investment firm Hg Capital from 2006 to 2012, responsible for acquisitions and portfolio management, and serving on the board of directors of several privately held European healthcare companies. He was a management consultant with Bain & Co. where he advised clients on growth strategies, operational improvement projects, mergers and acquisitions. Justin holds a bachelor of commerce and a bachelor of laws from the University of New South Wales, Sydney, and a master of business administration from the Harvard Business School.
How old is Justin Leong?
Justin Leong is 43, he's been the President – Asia and Latin America of Resmed since 2020. There are 22 older and no younger executives at Resmed. The oldest executive at Resmed Inc. is Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD, 79, who is the Founder & Non-Exec. Chairman.
Insiders trading at Resmed
Over the last 23 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace oraz David Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.
What does Resmed do?
at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.
What does Resmed's logo look like?
Complete history of Mr. Leong stock trades at Resmed
Resmed executives and stock owners
Resmed executives and other stock owners filed with the SEC include:
-
Michael Farrell,
Chief Executive Officer, Director -
Robert Douglas,
President, Chief Operating Officer -
Jim Hollingshead,
President – sleep and respiratory care business -
Rajwant Sodhi,
President – Software as a Service Business (SaaS) -
Brett Sandercock,
Chief Financial Officer -
Michael J. Farrell BE, SM, MBA,
CEO & Director -
David Pendarvis,
Chief Administrative Officer, Global General Counsel, Secretary -
Michael J. Farrell BE, MBA, SM,
CEO & Director -
Robert A. Douglas,
Pres & COO -
Dr. James R. Hollingshead Ph.D.,
Pres of Sleep & Respiratory Care Bus. -
Brett A. Sandercock,
Chief Financial Officer -
Peter Farrell,
Non-Executive Chairman of the Board -
Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD,
Founder & Non-Exec. Chairman -
Dr. Peter C. Farrell A.M., B.E., Ph.D., BE (Hons), ScD, AM,
Founder & Non-Exec. Chairman -
Ronald Taylor,
Lead Independent Director -
Carol Burt,
Independent Director -
Richard Sulpizio,
Independent Director -
Harjit Gill,
Independent Director -
Jan De Witte,
Independent Director -
Karen Drexler,
Independent Director -
Justin Leong,
President – Asia and Latin America -
Urvashi Tyagi,
Chief Technology Officer -
Nupur Bhushan,
Chief People Officer -
David B. Pendarvis,
Chief Admin. Officer, Global Gen. Counsel & Corp. Sec. -
Amy Wakeham,
VP of Investor Relations & Corp. Communications -
Constance C. Bienfait,
Director of Investor Relations -
Kaushik Ghoshal,
Pres of SaaS Bus. & CTO -
John P Wareham,
Director -
Christopher G Roberts,
Director -
Donald Darkin,
Sr. Vice President, Pat Inter -
Gary W Pace,
Director -
Anne Reiser,
President - ResMed Europe -
Richard Mc Hale,
President, RC Business -
Inc Resmed,
Director -
James Hollingshead,
President, Sleep Business -
Kieran Gallahue,
President, Global -
Paul Eisen,
Vice President, Europe & Asia -
Donagh Mccarthy,
Director -
Adrian M Smith,
CFO -
Klaus H Shindhelm,
Sr. Vice President, Operations -
Keith Serzen,
Chief Operating Officer -
Louis A Simpson,
Director -
Christopher Bartlett,
Director -
Walter Flicker,
VP and Asst. Corp. Secretary -
Lasse Beijer,
COO-Europe -
Stein Jacobsen,
COO, Europe -
Michael A Quinn,
Director -
Kaushik Ghoshal,
President, SaaS Business -
Lucile Blaise,
President, Sleep & RC Business -
John Hernandez,
Director -
Desney Tan,
Director -
Michael J Rider,
Global General Counsel -
Christopher Del Orefice,
Director